Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

153
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
153
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Drug Regulation01:25

Drug Regulation

1.5K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.2K
Pharmacovigilance01:19

Pharmacovigilance

933
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
933

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.

BMJ open·2026
Same author

Validation of Plasma Free Hemoglobin Testing for Extracorporeal Membrane Oxygenation (ECMO) Patients.

The journal of applied laboratory medicine·2026
Same author

The "pause" on the Canadian Task Force on Preventive Health Care is misguided.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2025
Same author

Unveiling chemical industry secrets: Insights gleaned from scientific literatures that examine internal chemical corporate documents-A scoping review.

PloS one·2025
Same author

Commentary: Which Principles Should Apply for a National Strategy on Rare Diseases?

Healthcare policy = Politiques de sante·2024
Same author

Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials.

International journal of health policy and management·2024

Related Experiment Video

Updated: Aug 6, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Commentary: Reconsidering Pharmaceutical Research and Development Investments.

Marc-André Gagnon1

  • 1Associate Professor, School of Public Policy and Administration, Carleton University, Ottawa, ON.

Healthcare Policy = Politiques De Sante
|March 14, 2023
PubMed
Summary

Canadian drug companies may inflate research and development (R&D) investments by including marketing costs. Statistics Canada

More Related Videos

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

8.5K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

Related Experiment Videos

Last Updated: Aug 6, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

8.5K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Evidence-Based Medicine

Background:

  • Canadian pharmaceutical industry R&D investment is a subject of ongoing debate.
  • Previous research by Lee et al. (2023) suggested Canadians are disadvantaged by drug companies' R&D investments.
  • Existing R&D definitions may not accurately reflect genuine innovation spending.

Purpose of the Study:

  • To provide further context on the debate surrounding pharmaceutical R&D expenditures in Canada.
  • To critically examine the definition and reporting of R&D investments by the pharmaceutical industry.
  • To assess the role of Statistics Canada and Innovative Medicines Canada in shaping the narrative on R&D.

Main Methods:

  • Rejoinder analysis of existing literature and industry practices.
  • Critical evaluation of R&D expenditure definitions.
  • Examination of the relationship between Statistics Canada and industry associations.

Main Results:

  • The current definition of R&D investment may be too broad, potentially including marketing activities like seeding trials.
  • Evidence suggests Statistics Canada collaborated with Innovative Medicines Canada to promote industry-favored R&D narratives.
  • This collaboration raises concerns about the reliability and independence of Canada's statistical agency.

Conclusions:

  • The definition and reporting of pharmaceutical R&D in Canada require stricter scrutiny.
  • The integrity of national statistical agencies is crucial and must be protected from industry influence.
  • Accurate R&D data is essential for informed policy decisions regarding drug pricing and innovation.